text:
316/365 - Zan celebrates with Fiona.
Fiona's favourite food in the world is nachos. We're not really very sure why, but it's like her superhero weakness. So to celebrate her today, we had nachos! :)
I had a lovely time with the girls, and had very good food. Sticky toffee pudding for dessert - warming hearty deliciousness! Made me soooo happy! :) Hoorah! :) Until next time, ladies! :) And happy birthday Fiona! :)


text:
Welcome to the
feedback page!
We created this forum to hear your ideas, feature suggestions and feedback on RtReports. Please suggest your most important features and design change ideas on this site, and vote for your favorite ideas.
Please note that your ideas and comments posted here are visible to all other users.
- For bugs, please open a case with OSIsoft Tech Support through myOSIsoft Customer Portal (https://my.osisoft.com) instead of sharing them on this site.
- For documentation feedback and bugs, please report to firstname.lastname@example.com instead of sharing them on this site.
Send notification to next approver-group in approval cycle
Provide the possability to send notifications based on the approval-cycle status of the report.
For example: In a "two-steps" approval cycle, send a notification to the final approval group when the first group approved the report.4 votes
Provide native 64-bit version of RtReports Server
Provide a native 64-bit version of the RtReports Server.4 votes
- Don't see your idea?

subset: commoncrawl


text:
Some $400 million in cryptocurrencies was recently sold from Mt. Gox, former Japanese bitcoin exchange giant, by the bankruptcy trustee handling their case. This detail was revealed by trustee Nobuaki Kobayashi, early this month.
According to his report, the exact amount was JPY 42,988,044,343. Mt. Gox liquidated as much as 35,841.00701 BTC and 34,008.00701 in bitcoin cash in total. As per Kobayashi:
"As a result of the consultation with the court, I considered it necessary and reasonable to sell a certain amount of BTC and BCC at this point and secure a certain amount of money for distribution resources, and thus, I sold the amount of BTC and BCC above. I made efforts to sell BTC and BCC at as high a price as possible in light of the market price of BTC and BCC at the timing of sale."
Apparently, this is just the beginning of many other liquidation processes, as more are very well on its way, pending approval of the court, as per Kobayashi. Currently, hhe has in his possession Mt. Gox assets worth 166,344.35827254 BTC. "I plan to consult with the court and determine further sale of BTC and BCC."


text:
Long, long ago, I opened up my messy brain to show you what I was planning for S's superhero themed bedroom. 6 months later the room is yet to be completed. Really, all I have left is the quilt. Want to know why it's still incomplete? After all of the unpacking and settling in this Fall, and my oldest asking for a new theme … [Read more...]
Superhero Bedroom
Being on vacation for the last month or so has given me plenty of time to start planning S's new "Big Boy" bedroom. If you've been following my Pinterest activity, you probably already know what it is. For those of you who use your time wisely and have yet to give into the wonderfully, creative "time vacuum" that is Pinterest . . . … [Read more...]
Turn a Deck of Cards into Wall Art
We found a fabulous deck of cards, chalk full of medievial knights, while visiting France last month. The entire deck is full of French knights. The served it's major purpose of entertaining the cheribs while waiting for our meals at restaurants and during the long car trip. Since then, I've spent endless hour playing 52 card pick up. … [Read more...]
Castle Wall Art
Still plugging away at the Knight themed bedroom. I actually feel a little guilty posting about this one because it's not . . . quite . . . done. I think. Or maybe it is? There's something about the white space behind the gate that bothers me but I'm not sure what to do about it. Do I paint it? Gray? I've also got … [Read more...]
A Knightly Freezer Paper Stenciled Pillow
I've decided that the title of this blog really should have been "A Work In Progress". Because really, that's my life summed up nice and neat for you. I've had grand plans for a Big Boy Bedroom Reveal but since the switch over to a Knight theme has been slow going, I thought I'd show you what's been completed so far. Let's start … [Read more...]
A YELLOW Dump Truck Pillow
It had to happen. Before I was even close to being ready, Dana over at Made put an end to her celebration of YELLOW. I've had so much fun watching everyone celebrate my favorite color through crafts. And because we were away this week (hee, hee. tricked you all with my stealthy, pre-scheduled posts), I totally missed … [Read more...]


text:
Chef white jackets long sleeve hidden steel buttons, kitchen stud long white coats
- Double breasted stylish unisex design
- Two rows of five stainless Steel Stud Buttons.
- Stand-up collar
- Pen/thermometer sleeve pocket.
- 65% Polyester, 35% Cotton for easy wash and comfortable wear
- Reinforced double stitched seam for longer durability
- Individually packed
- Comfortable and Durable


text:
Online Writery
We named it TONY.
Since the early 1990's, the Writing Center at the University of Missouri has been tutoring online submissions. As we celebrate our 41st year as Writing Center, we'd like to welcome you to version 5.
- Here's a how-to video for online submissions: How to Submit a Draft Online
- Here's a how-to video for scheduling appointments: How to Schedule an Appointment Online
Just like face-to-face appointments, submitting to the Online Writery is available to anyone with an MU pawprint and password. You can send us submissions for any writing project, including all course-related assignments, personal statements, cover letters, scholarship essays, creative writing pieces, or pretty much anything else you can think of that has sentences.
All submissions are free and completely confidential. The only difference: we never close.
A couple things that can go wrong: TONY does not support drag and drop functionality. TONY also doesn't work well with Internet Explorer. We recommend virtually any browser except Internet Explorer.


text:
|, Various Locations Glasgow
|Glasgow Science Festival Website
|Follow GlasgowSciFest on Twitter
|Facebook information can be found here
Glasgow Science Festival returns for the 13th year with a fantastic array of events for all ages. Explore the science and engineering that's shaping life on Earth through talks, art, film, experiments, family days and more!
From 6-16 June 2019 we're delighted to present a fresh programme of innovative events to spark your curiosity and trigger the imagination. Explore the science and engineering that's shaping life on Earth through talks, art, film, experiments, family days and more!
This year's theme is 'Glasgow STEAMS Ahead', linking with steam-engine innovator James Watt, who kick-started the industrial revolution and died 200 years ago.
We want to celebrate Glasgow's rich heritage and bright future for innovation. From renewable energy to space exploration and revolutionary healthcare, discover how 'weegie research is pushing boundaries and changing the world.
STEAMS encompasses not only Science, Technology, Engineering and Mathematics – but also the fantastic Arts and Social Sciences research that shapes our city.
We strongly believe that science is for everyone, from the weans to yer granny. So, don a metaphorical lab coat for the day and join us for Glasgow's biggest celebration of world-leading research.
Looking to reach new customers? We offer a variety of advertising options with prices starting from just £30 per month!


text: During your stay in Cambodia, you will most probably be touched by the kindness of the Cambodian people. In most places, you'll be warmly welcomed and guided by local residents, eager to show you the treasures of their country. Although your Cambodian hosts will do their best to tolerate tourists' involuntary mistakes, stemming from different cultural and social conventions, the following tips will help you understand Cambodian culture and avoid social misunderstandings.


text:
The American Farm Bureau Federation told the Agriculture Department it is concerned that even after the new mandatory country-of-origin labeling (COOL) program takes effect on Sept. 30, there still may be no exclusively U.S. labeled meat available to consumers.
In a letter this week to USDA Undersecretary Bruce Knight, AFBF President Bob Stallman said Farm Bureau is concerned about USDA's interpretation of COOL, as passed by Congress. USDA's interpretation would allow marketers to use a less-demanding "mixed origin" or "from multiple countries" label, even for meat that was exclusively U.S. born, raised and slaughtered. Instead, AFBF believes meat that is exclusively born, raised and slaughtered in the U.S. should carry an exclusive U.S.-origin label.
"There is now great concern that there will not be any exclusively U.S. labeled meat because many within the industry have said that the only label they will use is 'Product of the U.S., Canada or Mexico,'" Stallman stressed in his letter. "Farmers and ranchers are being told by some processors that unless they check the multiple-origin label box (to certify the origin of their animals) on their product affidavits, they will be audited. This information is completely discouraging to a producer, not to mention the fact that it is not a true statement."
Stallman asked USDA to conduct a "nationwide meat labeling survey" this year to determine how much product, which product and where exclusively U.S.-labeled meat is being sold. The survey will provide both producers and lawmakers objective information to determine if the COOL law or USDA's interim final rule on COOL should be amended to better allow for U.S.-origin labels.


text:
A man will face the Melbourne Magistrates Court today charged with the alleged murder of 20-year-old Rahat Khan on Tuesday.
The 28-year-old man was arrested by police last night and charged with one count of murder.
Mr Khan was allegedly shot on a Dallas street on Tuesday at around 5.30pm.
Paramedics worked to revive him, but he died at the scene.
His friend had driven him a short distance to Millewa Crescent from where Mr Khan was shot and pulled over to flag down help.
A funeral was held for Mr Khan yesterday.


text:
The Xtreme Fat Destroyer
Discover the
Fat scorching
secret everyone looking to
lose weight should know…
WARNING: Your about to learn one of the most powerful fat melting secrets that bodybuilders, hollywood celebrities and fitness gurus might not want you know…
Have you ever just looked at someone and thought to yourself "damn I wish I looked like that?"
We all have, lets face it… But the truth is YOU can create an amazing physique just like that one you've always admired
Ever since I was young I have been OBSESSED with creating an eye-grabbing physique. You know the one I'm talking about… The one that turns heads as soon as you walk into a room.
I would spend countless hours a day soaking up all I could about the science behind fat loss until one day my friend Mike came up to me.
He told me about the results he'd been getting with one of the fat burning methods I previously told him about.
When I told him about this fat melting trick it was just something I had learned about but didn't really understand the potential it carried.
He began to tell me that he had lost 12.5 lbs in just 14 days…
12.5 lbs in 14 Days…
The RESULTS were STAGGERING. I knew I was onto something.
Mike at the time had already tried the Atkins diet, the low-carb diet, weight watchers and even the workout program Insanity yet none of these delivered the results he was looking for.
That was until he learned this fat shedding secret.
He told me he was just tired of wasting his money on diet programs, supplements, workout routines, only to see minimal results.


text: 404 – PAGE NOT FOUND We probably moved something Unfortunately, you've left our playable area. Ask RED PHOG to FETCH what you're looking for! Search for: FREE STUFF SUBSCRIBE TO RECEIVE A DRM-FREE COPY OF CHIP Plus, get access to exclusive news and sneak peeks of games from us and our trusted partners. Data stored as outlined in our Privacy Policy. Success! Please check your email. Name Email Subscribe About Games Careers Partner Blog Contact © 2011 - 2019 COATSINK SOFTWARE LTD. ALL RIGHTS RESERVED. All trademarks referenced herein are the properties of their respective owners. Legal Privacy Policy


text:
Crucible Criminal Justice Programs (CCJP), is a highly-specialized provider of technology, engineering, security solutions and other demanding technical requirements in the national security and mission support operational space.
We serve the full range of federal stakeholders and industry partners with a security cleared workforce, delivering a wide range of integrated professional and engineering services in support of national security and law enforcement missions.
Our experienced team develops and delivers effective, best-value solutions to meet our clients' specific requirements, collaborating with clients and stakeholders to find innovative solutions to complex challenges.
CCJP is a Virginia-based, Small Business and a wholly-owned subsidiary of Garud Technology Services, Inc. (GTS).


text:
Communities (58)
- History 5.8k 5.8k 22 gold badges2323 silver badges6363 bronze badges
- Travel 2.2k 2.2k 1010 silver badges2727 bronze badges
- Politics 1.3k 1.3k 66 silver badges1212 bronze badges
- Interpersonal Skills 1.1k 1.1k 44 silver badges1010 bronze badges
- Mathematica 943 943 55 silver badges1616 bronze badges
- View network profile →
Top network posts
- 63 Why don't the other countries of Europe maintain as massive a military as Russia does?
- 53 Why does the Great Wall of China follow such a bendy route?
- 37 Why did the Chinese Nationalist party members go to the island of Taiwan and not to any other island?
- 37 Ask a girl whether she would like to come back to a hotel with me on a night out without being creepy
- 33 How can I avoid the awkwardness of a returning player who wears a low-cut shirt?
- 29 I'm losing it, with a talkative toddler, a colicky baby, chores, work, and lack of sleep
- 29 Why are so many metros underground? Isn't that more expensive than an elevated system?
- View more network posts →
Top tags (1)
Top posts (1) All Questions Answers | Votes Newest
Badges (7)
Jun 19
×2Sep 19


text:
List of Pharma Companies in Delhi
Abbott Healthcare
- Abbott is a worldwide broad based healthcare company whose products and technologies span the continuum of care – from diagnostics to devices, from nutrition to pharmaceutical therapies
- Abbott India Limited's success is driven by a combination of a highly competent and motivated commercial team, R&D backed products, aided by strong alliances and partnerships.
- Abbott India Limited employs over 2,600 people and reaches customers through a wide network of 35 distribution points, catering to over 4,500 stockists and 150,000 retail outlets.
Address: Plot No 137 1st Flr, Arjun Nagar, Kotla Mubarakpur, Delhi
Website: www.abbott.co.in
ABS Biotech
- ABS BIOTECH is a biotech management company involved in research, manufacturing, and marketing of high quality products.
- We are professionally managed team of young enthusiasts and always ready to serve your requirements to your entire satisfaction.
- Open culture, participative management practices, innovation, continuous improvement, speedy response, empowerment of individuals and enjoyment of one's job and contribution to the community are hallmarks of ABS BIOTECH.
Address: O-38, Vijay Vihar, Near Arya Samaj Road, Uttam Nagar, New Delhi
Website: www.absbiotech.net
Aimil Pharmaceuticals India
- AIMIL has been extensively engaged in manufacturing and sale of Generic & Proprietary categories of Quality Natural Products of herbo-mineral origin.
- From a very modest beginning with a turnover of Rs.10 Millions in 1985.
- The company has made long strides in emerging as one of the leading companies in Ayurvedic (herbo-mineral) medicines and is registering a continuous growth.
Address: 13/2, Naraina Industrial Phase – I, Delhi
Website: www.aimilpharmaceuticals.com
Akum Drugs & Pharmaceuticals Ltd Haridwar
- Akums Drugs & Pharmaceuticals Ltd. was incorporated on December 19th, 2004.
- This decision of the Company was historic in more ways than one.
- It was to mark the beginning of a long and eventful journey into Pharmaceutical Business.
- Over the years Akums has evolved from a manufacturer of few products into a fully integrated pharmaceutical company.
Address: 307, Nr Mother Diary, Rani Bagh, Delhi
Year Founded: 2004
Website: www.akums.in
Albert David Ltd
- Albert David Limited (ADL), a prominent drug house, distinguished in the field of manufacturing Pharmaceutical Formulations, Infusion Solutions, Herbal Dosage Forms, Bulk Drugs and Disposable Syringes & Needles has its base in Kolkata, India.
- The company belongs to a renowned industrial house of Kolkata, the "Kothari Group, India".
- Equipped with cutting edge research and development standard and scientific skill, the best brains work here to develop new products for the demanding marketplace worldwide.
Address: B-12/13, Indl Area, Meerut Rd, Meerut Road Industrial Area, Ghaziabad
Website: www.albertdavidindia.com
All India Biotech Association (AIBA)
- All India Biotech Association (AIBA) was established in 1994 as a non- profit Society to provide common Apex Forum at the national level to represent the interests of all those engaged in various aspects of Biotechnology.
- One of the main objectives of AIBA is to Promote and safeguard the overall interests of Biotechnology as a science, profession, industry & trade.
- In August, 1999, the Southern Chapter of AIBA has started Functioning at Hyderabad.
Address: VIPSS Centre , 2, Local Shopping Centre, Block EFGH, Masjid Moth, Greater Kailash-II, New Delhi
Year Founded: 1994
Website: www.aibaonline.com
Biotech Consortium India Limited
- BCIL was inaugurated in 1990
- Biotech Consortium India Limited (BCIL) is a public limited company, promoted by the Department of Biotechnology (DBT), Ministry of Science and Technology, Government of India and All India Financial Institutions for providing the necessary linkages among stakeholders and business support for facilitating accelerated commercialization of Biotechnology.
Address: 5th Floor, Anuvrat Bhavan, 210, Deen Dayal Upadhyay Marg, New Delhi
Year Founded: 1990
Website: www.bcil.nic.in
Cipla Ltd
- Cipla Global Limited is an Indian multinational pharmaceutical and Biotechnology company
- We are one of the world's largest generic pharmaceutical companies with a strong presence in over 170 countries.
- We maintain world-class quality across all our products and services.
Address: A-37, 2nd Floor, Cannaught Circus, Connaught Place, Delhi
Website: www.cipla.com
Dabur India
- Dabur India Limited has marked its presence with significant achievements and today commands a market leadership status.
- Our story of success is based on dedication to nature, corporate and process hygiene, dynamic leadership and commitment to our partners and stakeholders.
- The results of our policies and initiatives speak for themselves.
Address: Plot No-22, Site-5, Sahibabad Industrial Area, Ghaziabad
Year Founded: 1884
Website: www.dabur.com
Dr Morepen Laboratory
- Morepen's state-of-art manufacturing facility in the picturesque environs of Baddi comprises a scientifically integrated complex of 10 plants, each with a specific product profile.
- The company's extensive R&D facilities and factories are manned by a dedicated team of professionals who ensure stringent quality standards.
- Morepen is exporting products to several countries round the global.
Address: 409,Antriksh Bhawan,22, Kasturba Gandhi Mg, Connaught Place, Delhi
Year Founded: 1985
Website: www.morepen.com
GenPro Biotech
- GenPro Biotech was founded about a decade ago to cater to the needs of Research Community engaged in Life Sciences research.
- We started with a view that researchers need chemicals/ bio-chemical/immuno-chemicals as quickly as possible.
- We aim to provide some of these items to ur valued customers as fast as possible and at very reasonable in the global market.
- We strive to manufacture products of highest possible quality and believe in the philosophy of KAIZEN.
Address: 3022, Sector-A, Pocket B & C, Vasant Kunj, New Delhi
Website: www.genpro-biotech.com
Genxbio Health Sciences Private Limited
- Genxbio Health Sciences Pvt. Ltd is one of the fastest growing biotech group in India that has successfully entered the clinical path /nanotechnology and pharmaceutical product development space.
- GenxBio was established to provide the most comprehensive product range in the fields of biotechnology, molecular biology, genomics, proteomics and pharmaceuticals sciences for the international and national Life Science R&D communities.
- GenxBio has been providing unparalleled service and support to our customers by combining technical expertise, quality material and sound business strategies.
Address: Flat. no- 6, S-553-554, Ground Floor,, Shakarpur, New Delhi, DL
Website: www.genxbio.com
Glaxo Smithkline Consumer Healthcare
- GlaxoSmithKline plc (GSK) is a British multinational pharmaceutical, biologics, vaccines and consumer healthcare company which has its headquarters in Brentford, London.
- It was the world's sixth-largest pharmaceutical company after Johnson & Johnson, Novartis, Hoffmann-La Roche, Pfizer, and Sanofi, measured by 2013 revenue.
- The company was established in 2000
Address: Dlf Plaza Tower, PH-1,Dlf City, Dlf City Phase I Gurgaon
Year Founded: 2000
Website: www.gsk-ch.in
Glenmark Pharmaceuticals
- Glenmark is a leading player in the discovery of new molecules, both NCEs (new chemical entity) and NBEs (new biological entity), with seven molecules in various stages of clinical development & pre-clinical development.
- The company has a significant presence in branded generics markets across emerging economies including India.
- It's subsidiary, Glenmark Generics Limited has a fast growing and robust US generics business.
Address: Klj Complex 2, Moti Nagar, Delhi
Website: www.glenmarkpharma.com
International Centre for Genetic and Biotechnology
- The ICGEB is an international, nonprofit research organization.
- Established as a special project of UNIDO, it became fully autonomous in 1994 and now counts over 60 Member States.
- The International Centre for Genetic Engineering and Biotechnology provides a scientific and educational environment of the highest standard and conducts innovative research in life sciences for the benefit of developing countries.
- It strengthens the research capability of its Members through training and funding programmes and advisory services and represents a comprehensive approach to promoting biotechnology internationally.
Address: ICGEB Campus, P.O.Box: 10504, Aruna Asaf Ali Marg, New Delhi
Year Founded: 1994
Website: www.icgeb.org
KEE Pharma LTD
- Kee Pharma Limited is a well-established Delhi based pharmaceutical company that was started in 1957.
- KPL has a 300 strong work force that is made up of professional and dynamic individuals working together as a team to ensure that KPL is an efficient and professionally run organisation.
- Kee Pharma is an Innovative, Dynamic and Caring organisation.
- We strive to provide the best that modern medicine has to offer be it new dosage forms, revolutionary pharmaceutical molecules or biotechnologically engineered cures.
Address: A-1, Indl Area,PH-2,Comm Centre, Naraina, Delhi
Year Founded: 1957
Website: www.keepharma.com
Lupin LTD
- The company was named after the Lupin flower because of the inherent qualities of the flower and what it personifies and stands for.
- The Lupin flower is known to nourish the land, the very soil it grows in.
- The Lupin flower is also known to be tolerant of infertile soils and capable of pioneering change in barren and poor climes.
- The Lupin flower and bean pods have also long been used as food and sources of nourishment, thus protecting and nurturing life.
Address: 202, Aggarwal Plaza, Plot No-3, Dda Complex, Sectot-14, Prashant Vihar, Rohini, Delhi
Website: www.lupin.com
Mankind Pharma Ltd
- Mankind Pharma, the 8th largest Pharmaceutical Company of India, was incepted in 1995.
- We are amongst the top 5 fastest growing Pharmaceutical companies of India with an employee base of more than 10000 and heading towards a turnover of INR 3000 crores.
- We aspire to aid the community in leading a healthy life through two parallel objectives: formulating, developing & commercializing medicines and delivering affordable & accessible medication that satisfies urgent medical needs.
Address: 236, Okhla Industrial Area Phase III, Delhi
Year Founded: 1995
Website: www.mankindpharma.com
Mirik Health Foods
- MIRIK, a brand is synonymous with health and personal care developed from time – tested Ayurveda.
- Ayurveda, the ancient medical science of India, is not merely a doctrine of medical treatment of MIRIK, but a way of healthy and happy life.
- This young, fast growing and professionally managed FMCG/OTC/Cosmetics/Pharma Company produces more than 150 traditional products in accordance with the principles of Ayurveda
Address: 1110, Surya Kiran Building, Near Himalaya house, 19, K G Marg, Connaught Place, Delhi
Website: www.mirik.biz
ONGC Teri Biotech
- Oil and Natural Gas Corporation Limited (ONGC) and The Energy and Resources Institute (TERI) have a prolific association in the field of microbial biotechnology since 1996.
- The persistent efforts put in by scientists in microbiology laboratories of both ONGC and TERI for finding ways for enhanced oil recovery resulted in promising collaborative research.
- A long success story of the collaboration between ONGC and TERI culminated in the formation of ONGC TERI Biotech Limited (OTBL)
Address: TERI Complex, India Habitat Center, Lodhi Road, New Delhi
Year Founded: 1996
Website: www.otbl.co.in
Ozone Ayurvedics
- Ozone Ayurvedics is a Consumer Healthcare organization with expertise in Skincare.
- The company was established in the year 2000 with well-planned diversification into Herbal and Ayurvedics products and a vision to make use of the holistic approach of the ancient science of Ayurveda.
- Ozone Ayurvedics is an Ayurvedic Pharmaceutical Company operating under the aegis of Ozone Group of Companies.
- The company has played a major role in reviving and popularizing Ayurvedic medicine in India.
Address: 1, Local Shopping Cplx, Blk A-3, Nr Mata Charandevi Hospital, Janakpuri, Delhi
Year Founded: 2000
Website: www.ozoneayurvedics.com
Panacea Biotec
- Panacea Biotec values that strategic partnerships and collaborations can advance the availability of Affordable & high quality Products and Services across the globe.
- Panacea Biotec is committed to work closely with technology experts, academic institutions, distribution & marketing partners to leverage complementary strengths and contribute to advancement of affordable healthcare globally.
Address: B-1/A-27, Mohan Co-Operative Industrial Estate, Mathura Road, Delhi
Website: www.panaceabiotec.com
Pragati Biomedical
- Pragati Biomedical is a professionally managed company involved in marketing of products required by Bioresearch Laboratories & Healthcare industry.
- Our company is promoted by a team of committed technocrats with proven expertise in this field for more than a decade.
Address: 301-302,Agarwal Arcade,, Uttari Pitampura, New Delhi
Website: www.pragati-bio.com
Ranbaxy Laboratories Ltd
- Volini is a modern day pain reliever, scientifically formulated for effective pain relief.
- It can be used for Joint, Back, Neck & Shoulder pains, sprains & strains.
- 90% of the people who tried Volini found it better than their current pain relieving cream.
- By using Volini gel they experienced quicker, better & long lasting relief.
Address: Plot No-90, Gurgaon Sector-32, Gurgaon
Website: www.volini.com
Sysbiome Technologies
- Sysbiome Technologies provides end-to-end business solutions that leverage technology.
- We provide solutions for a dynamic environment where process and technology strategies converge.
- Our approach focuses on new ways of business combining innovation and adoption while also leveraging an organization's current assets.
- Our team works on innovative tools of new generation technology – to build new products or services and to implement prudent business and technology strategies in today's dynamic digital environment.
Address: 110, Gupta Arcade, LSC, Shrestha Vihar, New Delhi, DL
Website: www.sysbiome.com
Reliance Life Sciences
- The Reliance Group is India's largest private sector enterprise, with annual revenues of US$ 66.8 billion.
- The Group's activities span oil and gas exploration and production, petroleum refining, petrochemicals, polyester, plastics, organized retailing and telecom.
- The Group's flagship company Reliance Industries Limited is the largest private sector company and a Fortune Global 500 company.
- Reliance Life Sciences (RLS) is part of the Reliance Group of companies.
Address: Upper Grd Flr, Gopal DAS Bhawan 28, Barakhamba Rd, Connaught Place, Delhi
Website: www.rellife.com
Torrent Pharma
- Torrent Pharma, the flagship company of Torrent Group, is ranked amongst the top pharma companies of India.
- It is a dominant player in the therapeutic areas of cardiovascular (CV) and central nervous system (CNS) and has achieved significant presence in gastro-intestinal, diabetology, anti-infective and pain management segments.
- It has also forayed into the oncology therapeutic segment while also strengthening its focus on gynecology and pediatric segments.
Address: 115-116,World Trade Centre, Grd Flr, Babar Rd, Connaught Place, Delhi
Website: www.torrentpharma.com


text:
Wabash Avenue Presbyterian Church
307 South Washington Street
Directions from North: Take US Highway 231 (also named Washington Street within Crawfordsville city limits) south. Once you reach the courthouse, which will be on your left / east, continue south 2 blocks to the intersection of 231/Washington St. with Wabash Avenue. The church is located on the SW corner of that intersection. Turn right / west onto Wabash Avenue and then in 1/2 block turn left / south into the alley, which will lead you to our main / west parking lot. The entrance to the church is located across from the large silver maple tree in the playground.
Take US 231 (also named Washington Street within Crawfordsville city limits) north. Once you pass the large cemetery, which will be on your left / west, continue north 2 stoplights. After the 2nd stoplight (231/Washington and College Street), continue north 1.5 blocks. Once you cross Jefferson Street (which has no stoplight) the church is 1/2 block north on your left / west. Immediately after passing Powers & Priebe Funeral Home, turn left / west into our south parking lot. You may enter the church from the south parking lot via the Christian Education Wing Entrance, which is on the southwest corner of the building.


text:
Court Reporter in Queens County, NY | 866.357.1796 | New York Stenographers
Our court reporting agency is a full-service agency that provides apt court reporters and stenographers to help clients attain %accurate and easily accessible transcripts of all legal hearings such as arbitrations, mediations and depositions. If you're an lawyer who is looking for a certified court reporter, you can trust that we have everything you'll require to meet your needs. We come full equipped with videoconferencing technology and online services to attorneys and those who need to give or take a deposition.If you're looking for a certified court reporter in NY, Houston, New York, Philadelphia, Atlanta or anywhere else in the United States, turn to us for all your needs. We've been around for over two decades and have a successful track-record of not only meeting expectations, but exceeding them for our clients.
Stenographers and Conference Rooms New York
Our priority are our clients. We understand that when it comes to a legal hearing, such as a deposition, you will primarily be interested in obtaining the most accurate information possible. This is why we come fully staffed with experienced and knowledgeable court reporters, stenographers, videographers and interpreters who can provide you with the client-focused assistance you deserve. Aside from our certified court reporters and competent staff, our fully furnished conference room in New York comes with all the available resources and amenities you could need during your deposition. Our innovative technology ensures that you won't miss a single gesture, word or expression during the deposition.
Services we provide: Depositions – Hearings – Arbitrations – Mediations
- Court Reporters- Stenographers
- Legal Videographers
- Conference Rooms
- Video Conferencing
- Case Management
- Online Booking
- Video/Transcript Synchronization
- Video Editing
- Trial Presentation
- Interpretors
Court Reporters for Depositions | Legal Videographers | NY
Video is a powerful document in legal matters, particularly when those matters reach the courtroom and must be argued in front of a judge or jury. If you need a court reporting service to record and transcribe your deposition, make sure that they employ expert videographers with technology that can capture the most important visual details – positive or negative body language, facial expressions that don't match the tone of voice, and even the slightest gestures that might indicate witness coaching. A single nuance captured on video could make all the difference in the world when it comes to a settlement negotiation or a courtroom presentation.
Queens County New York
Court Reporting and Video | Online Calendar for Depositions | NY
One of the most important aspects of setting up your deposition is being able to schedule everything and work out the logistics for multiple parties. In fact, in the age of the internet, it is critical for attorneys to have access to an easy-to-use online system throughout the legal process, including the deposition stage. At a time when more and more people are using the internet to remotely pay bills and manage their daily affairs, it only makes sense that scheduling depositions and arranging for court reporters would also be done online.
Queens County New York
Court Reporters and Legal Videographers in New York
For court reporting in our number one priority is to help you in representing your client. Our exceptional court reporting services are available all across the country, so no matter where you practice law, you can count on us to provide you with the stellar service you deserve. Our adept team will be able to assist you in managing transcripts as well as any other vital legal documents. We're available for consulting and providing litigation support so you can easily access and send transcripts through the online document repository. Contact us today.


text: This is a spacious 1 bedroom with a phenomenal view of the Harlem River and NYC skylines. It is in estate condition so it needs some TLC, but once you are done, you will have your own beautiful perch in the sky! Riverpoint Towers is a full service, luxury building located in the Spuyten Duyvil section of Riverdale. Maintenance includes electricity, gas, heat, water, central air conditioning, basic cable w/internet service, 24hr doorman/concierge, seasonal outdoor heated pool, outdoor playground and community room. The building now offers a new gym for $400/yr membership. Parking also available. Close to local buses, express bus, 1 train, plus Metro North. Plenty of local shopping as well as restaurants. This is a must see unit! Sorry, no dogs. Must call agent for appointment during designated open houses


text:
I'm kicking off my series on wildlife in Liberia with the first part of the Libassa Wildlife Sanctuary in Marshall, Liberia. I took in so…continue
My followers know I am not one to shy away on the subject of rape and rape culture. Although the issue has been sensationalized recently…continue


text:
The north Indian community settled in either India and other sections of the world celebrate Karwa Chauth. Karwachauth is a festival that asks us to rely upon and celebrate the institution of being married. All married Hindu women observe a fast that ensures the well-being and longevity of their husbands on this day of the week.
For many holiday makers the prime reason to put together a visit to Coolangatta always be beaches. They are delightful, with excellent surfing spots but are patrolled to get your safety. You can choose from three beaches at "Cooly" as the locals call their neck of the woods - Coolangatta, Greenmount and Rainbow These types of. All are patrolled daily from 11.00am to 5.00pm unless the beach is closed.
So, imagine my shock when 7 days before my big 6-0, I fell into a great, big, dark funk. I spent three awful days convinced that I only agreed to be 20, and very soon I'd be 60, and where did final 40 years go? What did I've to show for of which? Certainly the days prior to me definitely lot less than the days behind me, and such like and and much more.
Fishing is actually many people choose to try. Ontario Lake country has lakes and waterways to sell. If you love fishing, this may be something verify, customer do while here. If you travels in the summer, they can savor the morning sunrise and enjoy fishing trip end in the dock, or troll a vessel around. If visits the actual winter, you can savor ice hiking.
Here's one of these. Go for mount batur sunrise trekking in an area you by no means have had the idea of. Perhaps its began on a fishing trip or helping poor natives their amazons, you will find solemn peace and serenity doing something that you simply would not normally implement.
Heading for you to Athens, your current quite several places of interest to conquer. Pelion, located between Athens and Thessaloniki, has mindful yourself . of all possible worlds There are long sandy beaches with clear turquoise water, but a short drive could have you in lush mountain villages with streams and traditional style homes made from stone. Your box is known for its herbs, vinegar, olive oil, and honey.
God invented sunrises and babies and fresh green grass and love. Much better than riches. DO NOT TIE YOUR HAPPINESS TO THE DOW! Challenges are just about all bad. These are challenges. We're living any financial challenge, that's almost.
For e-mail updates if a new article is posted, please subscribe at the top page and follow me on Twitter: @CapnDanny, GoogleBuzz, Facebook, or at News, Notes, and also the Who Dat Nation.


text:
Josie's Bingo every Saturday from 11am
July 13, 2019
10 Games Free, 10 games at $2
Bingo needs your help? Have a fun time with a chance to win up to $100k every week at bingo. Eyes down at 11am. Complimentary Tea & Coffee supplied. Bar Snacks at reasonable prices


text:
Good news! TEMPTING THEIR BEST FRIEND is up for pre-order at Amazon! Click here: http://amzn.to/2s59k9u
It's $0.99 until release day, after which it will revert to its usual price of $3.99. This is the first book in my series collaboration with Madison Blake, due to be published August 22! Oh, series title is No Holds Barred.
Cover: I've seen the draft and it's amazing! Sexy, naughty, exactly what this book is!
Edits: We're doing this presently, and we're nearing the finish line. *fingers crossed*
But what is the book about? You may ask in confusion.
Well, it features best friends–all three of them–some wicked shenanigans, naked time, and a gameboard! Madison and I are currently working on the blurb, but we leave you for the moment with this:
Tempting their best friend has never been so sweet…or delicious.


text:
Blasphemy is a hugely sensitive charge in conservative Muslim Pakistan and can carry the death penalty. Even unproven allegations can cause mob lynchings and violence. Photograph:( Zee News Network )
Two days after a Pakistani journalism student was lynched to death on a university campus for posting supposedly blasphemous content on social media, court officials said Saturday that eight fellow students were charged with murder and terrorism.
Police have arrested 45 people in connection with Mashal Khan's murder and are on the lookout for more students involved in the crime, Pakistani newspaper Dawn reported.
"Eight students were presented before an anti-terrorism court in Mardan over murder and challenging the writ of the state," public prosecutor Rafiullah Khan told AFP.
Mashal Khan -- who was studying at Abdul Wali Khan University -- was kicked, stripped and shot to death by a large mob in the conservative northwestern town of Mardan on Thursday.
Footage that was recovered showed several university students -- some of them allegedly student body leaders -- kicking and beating Khan's lifeless body with wooden planks, Pakistani media reported.
Mardan's Deputy Inspector General (DIG) of Police Mohammad Alam Shinwari said the 23-year-old victim died of a fatal gunshot.
The police official told Dawn that Khan was brutally murdered for "promoting the Ahmadi faith on Facebook".
Ahmadi Muslims have faced persecution since the movement began in the late 19th century. Sunni Muslims regard them as heretics.
The footage found at the crime scene also showed how people were forcing him to recite verses of Holy Quran. The video also showed Khan insisting that he was not an Ahmadi and did not promote it on Facebook.
Students had previously complained to university authorities about Khan's alleged secular and liberal views and Khan had been in a heated debate during a class the day he was killed.
Blasphemy is a hugely sensitive charge in conservative Muslim Pakistan, and can carry the death penalty. Even unproven allegations can cause mob lynchings and violence.
At least 65 people have been murdered by vigilantes over blasphemy allegations since 1990.
The independent Human Rights Commission of Pakistan (HRCP) has urged that all those involved in the lynching be brought to justice.
At his funeral on Friday, Khan's father said he hoped his son's murder would "evoke realisation among people that killing an innocent is a sin".
(WION with inputs from AFP)


text:
Updated: Dec 29, 2015
More than 300 actors entered the DAYS OF OUR LIVES "Search For A Star" Australian talent hunt, held in conjunction with Arena, the network that airs the soap Down Under. Last week, the three finalists -- Tom Dalzell, Andrew Steel and Alexander Bruszt -- did a screen test at the soap's Los Angeles studio for the role of Fynn, a rugged doctor who arrives in Salem to do his residency under Dr. Daniel Jonas.
The winner is expected to be announced this week, and the lucky gent will be awarded a 13-week contract with the soap. He'll make his Salem debut in late October, coinciding with DAYS' 50th Anniversary.


text:
Attractive tent decor and good quality hotelware are imperative demands of catering and hotel industries. Wedding ceremonies and grand level birthday parties look incomplete without excellent quality of Hotelware And Tent Decor Items. In making aforementioned product category available to hotels and event management companies, we, New Delhi (India) based Zeenat Hotelware And Tent Decor, are putting across our best. We make use of quality-assured materials in production process to avoid chances of defects in Fiber Decorative Products, Steel Catering Products etc. Each and every offering prior getting shipped, undergoes a wide series of quality tests. There is no company like ours to have business deals because we are both ethical and quality-focused. Keyfacts of Zeenat Hotelware And Tent Decor
Basic Information
Nature of Business
Manufacturer, Supplier
Company CEO
Faizan Ahmed
Year of Establishment
Company Branches
No. of Employees
No. of Designers
No. of Production Units
Monthly Production Capacity
As per Order
Production Type
Original Equipment Manufacturer
Warehousing Facility
Niche Market
Annual Turnover
Rs. 1 Crore
Statutory Profile
GST No.
Packaging/Payment and Shipment Details
Shipment Mode
By Road


text:
Day Visits
August 6th, 2013
A great Boland convention is waterblommetjiebredie (a delectable, hearty stew). Waterblommetjie (Aponogeton distachyos) literally denotes "water flower" and is endemic to the Western Cape. During the winter and spring months these slightly scented, fleshy white flowers drift on our valley ponds.
2kg waterblommetjies
1.2kg lamb shoulder in cubes
2 onions – finely chopped
3 cloves of garlic – finely chopped
3 lemons – juiced
500 ml lamb stock
500 ml Babylonstoren Chenin Blanc
10 baby potatoes – halved
4 large carrots – in medium sized cubes
4 leeks – halved and cut into 1cm slices
40 ml olive oil
30ml salt
Sea salt and black pepper
1. Cover the waterblommetjies with cold water in a large bowl. Add salt and let it soak until needed.
2. Heat the oil in a large heavy-bottomed saucepan. Brown the meat at high temperature.
3. Add onion and garlic to the meat and sauté until translucent.
4. Reduce the heat and add wine, lamb stock and lemon juice.
5. Cover and cook slowly until the meat is tender.
6. Add carrots, leeks, potatoes and waterblommetjies.
7. Continue cooking on low heat for about 30 minutes. But beware not to over-cook the waterblommetjies.
8. Season with sea salt and freshly ground black pepper.
9. Serve hot with rice or lentils.
* Soaking the waterblommetjies in salted water will get rid of any sand.
* Always use quality wine.
* For another layer of flavour add fresh thyme or oregano.
* Lemon juice will help the waterblommetjies retain colour.
* Slow cooking, over low heat brings out the best flavour in the dish, it also ensures that the ingredients doesn't go mushy.
[…] perfume. The highlights of the guided farm walks in winter include arum lilies and a Boland native, waterblommetjies, that grow in the vlei. After their summer siesta, the fynbos bulbs on the koppie will also […]


text:
Understanding The Schedule
The Studio, LDG Enrollment Tips/Guidelines ***At the Studio we work to place our kids in the best learning environment for their age, skill set and ability to focus and advance. Many studios will put 30 kids in a class because they all fall in the same age range of 8-10. The problem
Summer Dance Brochure Is Posted!
Click here to view a copy of the Summer Dance Brochure!
The Studio Liberty Dance and Glee Emphasizes Inclusiveness
We are proud to have recently been profiled on Kansas City Live! Click to see our interview here!
Fundraiser Info
Hey parents! Dont forget that the fundraiser is due Monday 10/9 and we absolutely can't take late orders so be sure to hand them in on Monday
One Family Film Info
Hey LDG families! If you were involved in the One Family film this last year, we have details on the local screening. It will be Wednesday, November 15 at 7 pm at B&B Northglen
Happy Birthday Miss Clair!!
This has all my fave pics of her so makes sense to use it again! Another year has gone by with another year of memories and "life". This beautiful girl came fresh out of college 6 years ago
Veteran Enrollment
Tomorrow, Saturday starts veteran enrollment for the 2017-2018 dance season! We will open the doors at 10 am
Welcome The 2017-2018 Studio Crew Members
Comp Tryouts are done..invites have been extended and acceptances have been handed in…so it brings me great pleasure to say congrats to our 2017-2018 Studio Crew Competition team….our biggest year yet with 78 team members and 43 dances for this year! Congrats to…Reagan, Lydia, Gracelynn, Emery, Emily, Brielle, Caylee, Annaliese, Bailey, Hannah, Cydney,


text:
|Salarievo Phase 1, Moscow, Russia
|PIK Group
|Landscape Architecture, Masterplanning and Urban Design
|Europe & Russia
The planned community of Salarievo is a leading example of landscape-led residential design in Moscow, Russia. The masterplan is inspired by its naturalistic surroundings, creating a dynamic community with a significant landscape at its heart that provides a canvas for family life.
Gillespies' landscape concept takes full advantage of Salarievo's beautiful naturalistic 'forest' setting, drawing nature right into the heart of the scheme through a myriad of verdant spaces - parks, squares, play-able zones and civic spaces - that offer a wide variety of settings for daily life, encouraging social interaction and creating a place where people want to live, work and play. The masterplan focuses on creating a 'liveable city' where walking, cycling, play and social interaction is encouraged and is key to the schemes success as a new residential quarter.
A boulevard or 'green spine' – surrounded by active frontages and interspersed with a series of public spaces – defines and connects the site from north to south together with a series of neighbourhoods, each defined by three linear parks. These linear parks are designed in such a way to be overlooked and defined by the surrounding built form. Six distinct neighbourhoods are formed by these linear parks, and connected by the main boulevard. They are referred to as Forest Neighbourhood, The Gateway, Green Park, Forest Enclave, Green Village and Woodland Town.


text:
Marble is a metamorphic rock that forms when limestone is subjected to the heat and pressure of metamorphism. It is composed primarily of the mineral calcite (CaCO3) and usually contains other minerals, such as clay minerals, micas, quartz, pyrite, iron oxides, and graphite. Under the conditions of metamorphism, the calcite in the limestone recrystallizes to form a rock that is a mass of interlocking calcite crystals. A related rock, dolomitic marble, is produced when dolo-stone is subjected to heat and pressure. Marble is perfectly suited to interiors due to its light and warmth and also its strength, shine and durability. The various processes of pressure and crystallization this material is subjected to, create a wide range of tones with different veining and flecks transforming it into a quality material which can easily be adapted to the needs of every project.
Egyptian marble Standard Specifications & Technical Data
- Water Absorption (ASTM C 97): 0.29 %
- Modulus of Rupture (ASTM C 99): 2000 psi
- Compressive Strength (ASTM C 170): 13300 psi
- Abrasion Resistance (ASTM C 24): 26.4 Ha
- Flexural Strength (ASTM C 880): 1600 psi
- Density (ASTM C 97): 2618
- Country of origin: Egypt
- Material availability: Blocks, slabs, tiles
- Dimensions of the slabs: 265-300cm x 160-195cm
- Thickness of the slabs (Availability): 15-20-30-40-50mm (up to 200mm by order)
- Dimensions of the tiles (Availability): Any dimensions
- Thickness of the tiles: 10-12-15-20-30-40mm (up to 200mm by order)


text: There are a lot of problems with Professor Oak's Pokedex mission -- the fact that he's entrusting a huge task to a 10 year-old, that he apparently hasn't studied any Pokemon despite being a "Professor," etc. But take the extraneous questions away and you still have the problem of the Pokedex mission itself. Here's how that conversation between Red and Oak would really go:


text:
We head to Grand Junction, Colorado, for The Lands End Hill Climb.
We check out Acura's new NSX, then we take a ride with Sebastian Vettel and IndyCar heads out to Detroit.
We check out Nissan's new Le Mans Prototype, then we have some fun on The Honda Grom and IndyCar heads out to Detroit.
We check out Honda's 2015 Motocross Team, then we talk with the owner of the first NISMO GTR delivered in the U.S. and Infiniti takes their Street-Car turned Track-Car to The Nürburgring Circuit.
IndyCar heads to the Barber Circuit in Alabama, MotoGP is in Spain at the Jerez Circuit and we talk to NASCAR Star Martin Truex Jr.
IndyCar heads to Long Beach for the Long Beach Grand Prix, NASCAR heads to Charlotte for the All-Star Race and we head to the Spa Circuit in Belgium to check out Bentley's GT3 Team in their first 24-Hour Race!
Former WRC Champion Juha Kankenen teaches students how to drive on snow, the Paul Miller Audi Team heads to Mazda Raceway in Laguna Seca and NASCAR heads to Bristol.
We check out Nissan's new Le Mans Prototype, The Red Bull Rookies Cup heads to Assen, Netherlands, then NASCAR goes to Texas.
We check out the Monterey Historics Race at Laguna Seca, where Sports Car legend Steve Millen brings back his 1994 Nissan 300SX Le Mans Winning Racecar. Then the NASCAR Truck Series heads to Atlanta and Rhys Millen in the Red Bull GRC Car takes to the streets of Washington D.C.
We check out Nissan's new Le Mans Prototype, NASCAR heads to Atlanta and the Red Bull Formula 1 drivers challenge each other to a Kart Race.
The Race Central crew heads to Daytona for the Sprint Unlimited, then we go behind the scenes with Mitsubishi's Pikes Peak Racecars. Also, we checkout the KPAX Racing's World Challenge Program.
The Race Central crew heads to the NOLA Motorsports Park for the IndyCar testing, then we check out the Lamborghini Super Trofeo and Nissan shows off their new Electric and Hybrid Racecars.
The Race Central Crew heads to The Arizona Open Wheel and Motorsports Hall of Fame to talk with USAC Legend Dave Darland. We also take a look at Bentley's GT3 Car and The Global Rallycross Series heads to Las Vegas.
The Race Central Crew heads to The Arizona Open Wheel and Motorsports Hall of Fame. The Bentley Team heads to Goodwood and Soccer Star Neymar Jr. tries his hand at being a WRC Co-Driver.
The Race Central Crew heads to Nuburgring for their 24 Hour Race, follows the Bentley Racing Team in Dubai and checks in with Sebastian Loeb.
The Race Central Crew heads to the Centennial Airport in Colorado, for The Morgan Adams Foundation Charity Car Show.
The Race Central crew heads to the Centennial Airport in Colorado, for the Morgan Adams Foundation Charity Car Show.
The Race Central crew talks to Matt Kenseth in Phoenix, then heads to Golden, Colorado, for the Mile High Nationals Pre-Race Kickoff Event and we also check out the Red Bull Air Races at Texas.
The Race Central crew heads to South Africa for the Red Bull X-Fighters, then we check out 'Mad' Mike Whiddett's Radbul project and the Global Rallycross Series heads to Daytona.
The Race Central Crew sits down with IndyCar star Justin Wilson and J.R. Hildebrand.
We take a look at the Maserati Trofeo, the 24 Hours of Spa, then Rhys Millen takes a drive in downtown Washington D.C. in his Rallycross Car and finally the Red Bull X-Fighters invade Germany.
We take a look at the Red Bull Ring Formula 1 Track in Austria, check out the Red Bull MotoGP Rookies Cup and the Global Rallycross Series invades Washington, D.C.
We take a look at the Super Trofeo Series, a look at Mark Webber's transition to Porsche and check out the New Bentley.
This week we sit down for an Exclusive Interview with NASCAR Sprint Cup Driver Martin Truex Jr.
We look at the New Lamborghini Huracon, check out the Red Bull Braveman competition and Peugeot's New Dakar Challenger.
We look at the New Honda Civic Type R, take a Road Trip in the New Bentley and head to The UCI Mountain Bike World Cup.
We head to the Mopar headquarters to check out their Brand New Monster Trucks, The Red Bull Air Races head to Croatia and The Red Bull Formula 1 Team does a Demonstration Run in Kuwait City.
Coverage of the final round of the Pirelli World Challenge Series and a look at Red Bull Hare Scramble Champion Graham Jarvis.
We check out Freestyle MX, ride along with Dale Earnhardt Jr. during the final laps of the Daytona 500, then chat with Red Bull Air Race Pilot Pete McLeod.
We hear from IndyCar Legend Dario Franchitti, check out The Red Bull Air Races and Urban Downhill Mountain Bike Racing.
Legends Car Racing from Colorado, then the Red Bull Plane shows off its tricks and finally we get an inside look at the New Lexus IS F.
We take a closer look at the Red Bull Toro Rosso Team, Freestyle Riding in Manizales and the Top Motocross Riders take on The Red Bull Straight Rhythm.
We check out Professional Skier Alexis Pinturault, the Lamborghini Super Trofeo Series and the New Bentley's at the Goodwood Festival of Speed.
We check out the Red Bull F1 Team as they make a surprise visit for an exhibition at the Burj Al Arab in Dubai, Freestyle Motocross in Azerbaijan, then we look at the New Lexus LS.
We check out Red Bull's 2014 Dakar program, the Hard Enduro Race and the Trolley Grand Prix.
We go drifting at the Red Bull Car Park Drift, then we check out the Red Bull Kart Fight and Mountain Biking at the Red Bull Rampage.
Behind the scenes at Mopar Mile High Nationals, we hear from the Red Bull Stratos Team and much more!
We check out the SCCA World Challenge Series from Sonoma, California.
A preview of the Red Bull Hard Enduro and highlights from The America's Cup.
Volvo Ocean Race, Maserati Trofeo World Series, Red Bull Battle in the Bay.
Red Bull MotoGP Rookies Cup, Rally and Drift Champion Abdo Feghali, Trial X Athletes and much more.
Keep up to date with changes and updates to Lucas Oil Racing TV via our email newsletter.


text:
Prognostic Impact of Staged Versus "One-Time" Multivessel Percutaneous Intervention in Acute Myocardial InfarctionAnalysis From the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial
Author + information
- Received September 19, 2010
- Revision received February 14, 2011
- Accepted February 22, 2011
- Published online August 9, 2011.
Author Information
- Ran Kornowski, MD⁎,⁎ (ran.kornowski{at}gmail.com),
- Roxana Mehran, MD†,
- George Dangas, MD, PhD†,
- Eugenia Nikolsky, MD‡,
- Abid Assali, MD⁎,
- Bimmer E. Claessen, MD‡,
- Bernard J. Gersh, MD§,
- S. Chiu Wong, MD∥,
- Bernhard Witzenbichler, MD¶,
- Giulio Guagliumi, MD#,
- Dariusz Dudek, MD⁎⁎,
- Martin Fahy, PhD‡,
- Alexandra J. Lansky, MD††,
- Gregg W. Stone, MD‡,
- HORIZONS-AMI Trial Investigators
- ↵⁎Reprint requests and correspondence:
Dr. Ran Kornowski, Cardiac Catheterization Laboratories, Department of Cardiology, Rabin Medical Center, Jabotinsky Road, Petah Tikva 49100, Israel
Objectives The purpose of this study was to compare a one-time primary percutaneous coronary intervention (PCI) of the culprit and nonculprit lesions with PCI of only the culprit lesion and staged nonculprit PCI at a later date in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease.
Background In patients with STEMI and multivessel disease, it is unknown whether it is safe or even desirable to also treat the nonculprit vessel during the primary PCI procedure.
Methods In the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial, 668 of the 3,602 STEMI patients enrolled (18.5%) underwent PCI of culprit and nonculprit lesions for multivessel disease. Patients were categorized into a single PCI strategy (n = 275) versus staged PCI (n = 393). The endpoints analyzed included the 1-year rates of major adverse cardiovascular events and its components, death, reinfarction, target-vessel revascularization for ischemia, and stroke.
Results Single versus staged PCI was associated with higher 1-year mortality (9.2% vs. 2.3%; hazard ratio [HR]: 4.1, 95% confidence interval [CI]: 1.93 to 8.86, p < 0.0001), cardiac mortality (6.2% vs. 2.0%; HR: 3.14, 95% CI: 1.35 to 7.27, p = 0.005), definite/probable stent thrombosis (5.7% vs. 2.3%; HR: 2.49, 95% CI: 1.09 to 5.70, p = 0.02), and a trend toward greater major adverse cardiovascular events (18.1% vs. 13.4%; HR: 1.42, 95% CI: 0.96 to 2.1, p = 0.08). The mortality advantage favoring staged PCI was maintained in a subgroup of patients undergoing truly elective multivessel PCI. Also, the staged PCI strategy was independently associated with lower all-cause mortality at 30 days and at 1 year.
Conclusions A deferred angioplasty strategy of nonculprit lesions should remain the standard approach in patients with STEMI undergoing primary PCI, as multivessel PCI may be associated with a greater hazard for mortality and stent thrombosis. (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction [HORIZONS-AMI]; NCT00433966)
Coronary reperfusion through the expeditious use of primary percutaneous coronary intervention (PCI) targeted primarily at the culprit lesion improves the outcome of patients with ST-segment elevation myocardial infarction (STEMI) (1). However, in STEMI patients, multivessel coronary disease is often encountered and poses a therapeutic dilemma, for example, whether to treat the nonculprit lesion/vessel at the same setting. In nonshock STEMI patients, the American College of Cardiology/American Heart Association and European Society of Cardiology guidelines support the use of primary PCI directed only at the infarct-related artery, with PCI of the nonculprit lesions guided by objective evidence of residual ischemia at later follow-up (2,3). Since large-scale, prospective randomized clinical trials are lacking to guide the appropriateness of complete revascularization during the course of STEMI, it is yet unknown whether it is safe or even desirable to also treat the nonculprit vessel during the acute infarction phase.
The large-scale prospective HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial randomly assigned STEMI patients undergoing primary PCI to bivalirudin alone compared to heparin plus a glycoprotein IIb/IIIa inhibitor (GPI), and to the use of TAXUS Express paclitaxel-eluting stents versus Express bare metal stents (both Boston Scientific, Natick, Massachusetts) (4–6). We, therefore, analyzed the HORIZONS-AMI database to explore the impact of a single "1-time" intervention (PCI of culprit and nonculprit lesions together) versus PCI of the culprit lesion only with staged nonculprit PCI at a later date.
Study protocol
The HORIZONS-AMI study design has been previously described in detail (4–6). In summary, the HORIZONS-AMI study was a prospective, open-label, randomized, multicenter trial in which 3,602 patients with STEMI presenting within 12 h of symptom onset and undergoing a primary PCI management strategy were randomly allocated equally in the emergency department using a computerized interactive voice response system to bivalirudin alone versus unfractionated heparin plus a GPI (the control group). After angiography, eligible patients were randomly allocated again in a 3:1 ratio to either TAXUS Express paclitaxel-eluting stents or otherwise identical uncoated Express bare metal stents. The study was approved by the institutional review board or ethics committee at each participating center, and all patients signed informed consent.
Patient eligibility has also been described previously (4–6). In summary, consecutive patients ≥18 years of age with symptom onset within 12 h of duration and ST-segment elevation of ≥1 mm in ≥2 contiguous leads, new left bundle branch block, or true posterior MI were considered for enrollment. Principal exclusion criteria included contraindications to any of the study medications; prior administration of fibrinolytic therapy, bivalirudin, GPI, low molecular weight heparin, or fondaparinux for the present admission (prior unfractionated heparin was allowed); current use of warfarin; history of bleeding diathesis, conditions predisposing to hemorrhagic risk, or refusal to receive blood transfusions; stroke or transient ischemic attack within 6 months or any permanent neurologic deficit; recent or known platelet count <100,000 cells/mm3 or hemoglobin <10 g/dl; planned elective surgical procedure that would necessitate interruption of thienopyridines during the first 6 months after enrollment; coronary stent implantation within 30 days; and noncardiac comorbid conditions with life expectancy <1 year or that might result in protocol noncompliance.
Clinical follow-up was pre-specified at 30 days, at 1 year, and yearly thereafter for 3 years total in all patients, with the exception of patients in whom all measured cardiac biomarkers were within normal limits and no coronary artery lesions were present with a diameter stenosis >50% by core laboratory determination; these patients required only 30-day follow-up.
Patients and study analysis
Of the 3,602 STEMI patients enrolled in the trial, 668 patients (18.5%) underwent PCI for multivessel coronary artery disease. Per operator discretion, PCI of the nonculprit lesions and vessels could be performed either during the acute infarct procedure (after successful treatment of the infarct-related artery), or in a separate staged procedure. A total of 275 patients (41%) underwent a 1-time multivessel procedure, whereas staging was performed in 393 (Fig. 1A). Patients undergoing multivessel PCI were further stratified by excluding from both groups all patients in whom the second lesion was in a vessel with Thrombolysis In Myocardial Infarction (TIMI) flow grade 0 to 2, in whom emergent nonculprit PCI might have been required. This latter classification thus defined 2 "true elective" multivessel PCI groups, namely, 165 patients with 1-time multivessel intervention and 77 patients with staged elective multivessel PCI (Fig. 1B).
Study endpoints
The study endpoints for the current analysis included the 1-year rates of major adverse cardiovascular event (MACE) and its components, consisting of death, reinfarction, ischemia-driven target vessel revascularization, and stroke. Stent thrombosis events were also adjudicated. Major bleeding (not related to coronary artery bypass graft surgery) and net adverse clinical events (NACE), defined as major bleeding or composite MACE, were additional pre-specified endpoints included in the original study and reported in the current analysis. The definitions of major bleeding and the individual component of MACE have been previously reported (4–6). Stent thrombosis was defined as the definite or probable occurrence of a stent-related thrombotic event, according to the Academic Research Consortium classification (7). An independent Clinical Events Committee blinded to treatment assignment adjudicated all primary endpoint and stent thrombosis events using original source documents.
Statistical methods
The present study represents a pre-specified analysis from the HORIZONS-AMI trial. Categorical outcomes were compared by chi-square or Fisher's exact test. Continuous variables were compared by the Wilcoxon rank-sum test. The primary event analyses were performed using time-to-event data (for which patients were censored at the time of withdrawal from the study or at last follow-up), displayed using Kaplan-Meier methodology, and compared with the log-rank test. Cox proportional hazards regression was performed to determine the independent predictors of all-cause mortality at 30 days and 1 year. Variables were selected using a forward stepwise algorithm with entry and stay significance levels of 0.1.
Our multivariate model tested 2 analytical methods. First, we included in the multivariate model only selected covariates that are expected to be related to long-term outcomes. Then, to avoid an "over-fitting" problem due to relatively large number of variables and fewer outcome events, we used an additional propensity score model for each outcome category that tests single versus staged PCI using only the propensity score as a covariate. This covariate refers to a variable for the propensity to undergo multivessel intervention. It was developed using a logistic regression model and was aimed to reduce selection bias in the elected treatment strategy (i.e., single/deferred versus multivessel PCI strategy) and its potential impact on measured outcomes.
The propensity was adjusted for age, drug-eluting stent use, dyslipidemia, smoking history, prior coronary artery disease or peripheral vascular disease or stroke, Killip class ≥2, pre-randomization heparin treatment, and clopidogrel loading dose. Also, this method allowed us to reduce more effectively the number of covariates when outcome event counts were relatively low in our study. The elected variables that were included in the original model are listed as follows: age, sex, Killip class, anemia, creatinine clearance <60 ml/min, bivalirudin use (vs. unfractionated heparin plus GP IIb/IIIa), history of diabetes mellitus, clopidogrel loading dose (600 vs. 300 ng), pre-randomization heparin, symptom to first balloon time, left anterior descending artery disease, pre-TIMI flow grade, left ventricle ejection fraction (LVEF), and single vessel versus multivessel PCI.
Patients and procedures
The median time interval between the first and second PCI procedures in the staged group was 30 days (range 6.0 to 51 days). The 2 groups were well matched (Table 1). The median baseline LVEF was not significantly different between groups, but more patients in the single PCI arm had a left ventricular ejection fraction ≤40% (20.5% vs. 11.1%, p = 0.002). Baseline medications were similar between groups (data not shown). Pre-intervention TIMI flow grade 0/1 in the culprit vessel was more prevalent in the staged PCI group (by both operator report and quantitative coronary angiography). The final angiographic culprit lesion rate of TIMI flow grade 3 was high (>90%) and similar between groups per operator report, but slightly less frequent in the staged PCI group per quantitative coronary angiography (86.7% vs. 91.7%, p = 0.02). Bivalirudin and GPI treatments were distributed equally among groups (Table 1). However, randomization to the TAXUS stent was more frequent in the single PCI group versus staged PCI group (81.5% vs. 72.3%, p = 0.009).
In the 1-time group as compared to the staged PCI group, the average number of stents implanted during the index procedure was higher (2.2 ± 1.1 vs. 1.7 ± 1.0, p < 0.0001), the number of vessels treated was greater (1.5 ± 0.5 vs. 1.0, p < 0.0001), the number of lesions treated was greater (1.7 ± 0.7 vs. 1.2 ± 0.5, p < 0.0001), the mean total stent length was greater (37 mm vs. 28 mm, p < 0.0001), a greater amount of contrast was utilized (275 ml vs. 235 ml, p < 0.0001), and the mean total fluoroscopy time was longer (16.0 min vs. 11.0 min, p < 0.0001).
Clinical outcomes
Table 2 summarizes the adverse events occurring through 1 year of follow-up for both groups. At 1 year, patients undergoing 1-time versus staged multivessel PCI had a significantly greater rate of all-cause mortality (9.2% vs. 2.3%, hazard ratio [HR]: 4.10, 95% confidence interval [CI]: 1.93 to 8.86, p < 0.0001) and cardiac mortality (6.2% vs. 2.0%, HR: 3.14, 95% CI: 1.35 to 7.27, p = 0.005). A higher mortality rate was present at 30 days after STEMI (all-cause mortality 5.8% vs. 1.5%, HR: 3.81, 95% CI: 1.51 to 9.62, p = 0.002; and cardiac mortality 5.5% vs. 1.5%; HR: 3.57, 95% CI: 1.40 to 9.09, p = 0.004). Time to mortality and cardiac mortality curves for patients with multivessel PCI, distinguished by revascularization strategy, are shown in Figure 2.
At 1 year, patients undergoing 1-time compared to staged PCI also experienced more stent thrombosis events, especially more "definite" stent thrombosis events within the first month after STEMI. There was no significant difference in the rate of reinfarction or target vessel revascularization between groups (Table 2). The composite MACE endpoint at 1 year (death, reinfarction, target vessel revascularization for ischemia, and stroke) tended to be higher in the 1-time PCI arm, although the overall difference did not reach statistical significance (18.1% vs. 13.4%, p = 0.08).
Major and minor bleeding complications rates were also significantly increased in the 1-time versus staged PCI groups according to some but not all of the definitions (Table 2). At 30 days, NACE was significantly higher among patients undergoing 1-time versus staged PCI (16.0% vs. 9.7%, HR: 1.72, 95% CI: 1.12 to 2.66, p = 0.01). However, the difference in NACE between groups was attenuated by 1 year so the difference was no longer significant (23.5% vs. 19.2%, HR: 1.29, 95% CI: 0.92 to 1.80, p = 0.14).
True elective procedures
After excluding patients in whom the nonculprit lesions were in vessels with TIMI flow grade 0 to 2, the 2 remaining groups (representing the "true" elective multivessel PCI groups) were again well matched for baseline features (data not shown), although the mean ejection fraction was lower in the 1-time PCI group (50% vs. 55%, p = 0.01). Patients undergoing elective 1-time multivessel PCI (n = 165) compared to a staged PCI strategy (n = 77) had higher 1-year rates of all-cause mortality (8.0% vs. 1.3%, p = 0.04) and cardiac mortality (4.9% vs. 0%, p = 0.05) (Fig. 3).
Multivariable analysis
The staged versus 1-time multivessel PCI strategy was independently associated with lower all-cause mortality at 30 days and at 1 year (Table 3). The finding of staged PCI being a predictor of reduced mortality persisted after adjusting the model for the observed covariable and also using the "propensity score" as the only covariable used in the second model (Table 3, lower part). Additional variables that also predicted mortality were Killip class ≥2 and measured creatinine clearance <60 ml/min.
Staged versus single PCI was also and independent predictor for improved MACE at 30 days and 1 year. Additional variable that were independently correlated with improved composite MACE are shown in Table 3. Finally, a strong similar trend for reduced mortality in favor of the staged PCI approach was also present in the true elective PCI cohort at 1 year after STEMI event (HR: 0.15, 95% CI: 0.02 to 1.11, p = 0.06).
Multivessel disease encountered during the course of STEMI PCI poses a therapeutic dilemma (8–16). It is also associated with an adverse prognosis among STEMI patients after primary PCI (8–16). Whether multivessel intervention during the index primary PCI procedure is safe has been the matter of debate. Some (10–12), but not all (8,13) studies have suggested that this practice is associated with increased mortality and reinfarction. More recently, advances in PCI techniques and adjunctive pharmacotherapy have led some operators and investigators to advocate a single-setting multivessel PCI strategy during the index STEMI procedure (8,9). The present analysis from the large-scale, contemporary and prospective international HORIZONS-AMI trial strongly suggests that a deferred angioplasty strategy for nonculprit lesions should remain the standard approach for patients with STEMI and multivessel disease undergoing primary PCI. Compared to a staged treatment approach, multivessel PCI that included nonculprit vessels during the acute STEMI reperfusion procedure was strongly associated with a greater hazard for 1-year all-cause mortality, cardiac mortality, MACE, and stent thrombosis. Even after multivariable correction for the baseline and post-procedure differences between the groups and also after using propensity score matching, staging the intervention remained a powerful independent predictor of enhanced survival. These findings also persisted after excluding all patients in whom the second nonculprit lesion was in a vessel with compromised angiographic epicardial flow, for which PCI was arguably "needed" during the index procedure. Thus, pending the results of a definitive randomized trial, a multivessel PCI strategy during the course of STEMI cannot be recommended as a routine approach in patients requiring multivessel intervention.
Our results are in accordance with the current American College of Cardiology/American Heart Association guidelines, which state that elective PCI should not be performed in a noninfarct-related artery at the time of primary PCI of the infarct-related artery in patients without hemodynamic compromise (Class IIIc indication) (2). Similarly, the European Cardiology Society guidelines state that in patients with multivessel disease, primary PCI should be directed only at the infarct-related artery; decisions about PCI on nonculprit lesions should be guided by objective evidence of residual ischemia at later follow-up (3). Notably, those recommendations were based on relatively small observational studies. Thus, the present analysis from 1 of the largest PCI trials performed up to date provides important complementary and supportive data to the existing literature on which these guidelines are based.
The reasons why multivessel intervention during the index primary PCI procedure may not be safe are unknown, but are likely multifactorial. Any PCI procedure is challenging in the setting of hemodynamic instability and left ventricular dysfunction. The prothrombotic and inflammatory milieu in the early phase of STEMI may also increase procedural risks (17–19). Consistent with this mechanism, the incidence of stent thrombosis in the present study was increased in patients undergoing a single setting rather than staged multivessel intervention. Second, lesion severity in nonculprit vessels can be overestimated at the time of primary PCI because of diffuse coronary vasoconstriction and systemic endothelial dysfunction (20); rarely are noninvasive testing data available or the time taken to perform fractional flow reserve in this setting to guide multivessel intervention. Third, multivessel PCI increases contrast use, which may be less well tolerated in the patient with STEMI, especially if radiocontrast nephropathy develops (21). Finally, unforeseen periprocedural complications in the nonculprit vessel may be poorly tolerated due to the "double jeopardy" of large myocardial territories at risk (i.e., simultaneous impairment of the culprit and nonculprit regions).
Conversely, there are numerous reasons why multivessel PCI during the index procedure may be desirable. Plaque instability may not be limited to culprit lesions, and may result in recurrent ischemia and infarction (22). The SWISSI II (Swiss Interventional Study on Silent Ischemia Type II) randomized trial demonstrated that the presence of silent ischemia after AMI is associated with a significantly higher rate of cardiac death and major adverse events if not treated (14). Complete coronary revascularization has been associated with a better long-term cardiac prognosis and improved left ventricular function (13). Finally, the 1-time PCI strategy may be cost saving, and decrease the need for future hospitalizations and procedures. It is possible that the findings from the present and previous nonrandomized studies are due to selection bias and the presence of unmeasured confounders in the single-setting multivessel PCI group that necessitated earlier nonculprit intervention.
To address these issues, 2 small randomized trials have recently been performed. Politi et al. (23) assigned 214 STEMI patients with multivessel disease to culprit-lesion only PCI, 1-time multivessel PCI, or staged multivessel PCI treatment (23). In-hospital death, repeat revascularization, and rehospitalization occurred more frequently in the culprit-lesion angioplasty group (all p < 0.05). However, after a mean follow-up period of 2.5 years, there were no significant differences among the 3 groups in terms of death or MI. The HELP-AMI (Hepacoat for Culprit or Multivessel Stenting for Acute Myocardial Infarction) study was a small multicenter randomized study (n = 69) that performed an unbalanced randomization and compared culprit lesion treatment only (n = 17) to complete "1-time" multivessel PCI (n = 52) during STEMI (11). The study found the 1-time multivessel strategy was safe but not necessarily justified based on subsequent need for clinically driven revascularization procedures and/or economical considerations. However, both trials were under-powered for the endpoints examined. The APEX-AMI (Assessment of Pexelizumab in Acute Myocardial Infarction) trial was designed to explore the incidence of and propensity for nonculprit interventions performed at the time of the primary PCI and its association with 90-day outcomes (24). Of the 5,373 patients who underwent primary PCI in this analysis, 2,201 had multivessel disease, and of those, only 217 (9.9%) underwent noninfarct-related arteries PCI. Ninety-day death and death/heart failure/shock were higher in the noninfarct-related group compared with the culprit only PCI group (12.5% vs. 5.6%, p < 0.001, and 17.4% vs. 12.0%, p = 0.020, respectively). After adjusting for patient and procedural characteristics as well as propensity for performing nonculprit PCI, this procedure remained independently associated with an increased hazard of 90-day mortality (adjusted HR: 2.44, p < 0.001). In addition, analysis of 1,598 patients enrolled in the EUROTRANSFER Registry database showed that in STEMI patients treated using emergent PCI, multivessel disease was identified as an independent predictor of 1-year death (25). In 70 patients (9%), nonculprit PCI was performed during the index PCI. These patients were at higher risk of 30-day and 1-year death compared to patients with culprit only PCI. However, this difference in mortality was no longer significant after adjustment for covariates.
Study limitations
In addition to the issue of residual confounding, several limitations of the present analysis warrant discussion: 1) although pre-specified, the present study is a retrospective nonrandomized subanalysis from a pivotal prospective randomized trial; 2) the cohort of 668 patients with STEMI undergoing multivessel PCI (41% during the index procedure) may still be under-powered to assess subtle distinctions between the 2 strategies; and 3) the specific reasons why operators chose a single procedure versus a staged approach was not prospectively collected. Despite our efforts to eliminate bias due to the nonrandomized nature of the comparison, we cannot totally refute the possibility that such bias actually existed and was not identified or eliminated in our careful statistical model. We have made our best attempt to reduce the impact of treatment bias by adding the propensity score covariate to the multivariate model. Although the event count was relatively low, findings remained with propensity score adjustment. Thus, the likelihood of a bias effect to explain our results is small.
These limitations notwithstanding, the results of the present study clearly suggest that a routine emergent multivessel PCI during the course of STEMI should be strongly discouraged. This is because it is associated with a greater hazard for subsequent mortality, stent thrombosis, and MACE in comparison to a staged PCI strategy. In the present analysis, we could not determine or compare the culprit vessel versus the nonculprit vessel PCI as this information has not been systematically recorded in the HORIZONS database. Thus, in summary, pending the results of a properly designed randomized trial, a deferred angioplasty strategy of nonculprit lesions should remain the standard approach to patients with STEMI and multivessel coronary artery disease.
The study was supported by the Cardiovascular Research Foundation and with grant support from Boston Scientific and Medicines Company. Dr. Mehran has received lecture fees from Boston Scientific and The Medicines Company; is a consultant to/on the advisory board of Abbott Vascular, AstraZeneca, Ortho McNeil, and Regado Biosciences; and has received a research grant from BMS/Sanofi-Aventis. Dr. Dangas reports receiving lecture fees from Abbott Vascular, AstraZeneca, Cordiva, Cordis, and The Medicines Company; consulting fees from Regado Biosciences; and research suppport from BMS/Sanofi-Aventis. Dr. Nikolsky is a consultant for Medtronic Cardiovasular. Dr. Gersh has received consulting fees from or serving on advisory boards for AstraZeneca, Bristol-Myers Squibb, Abbott Laboratories, Boston Scientific, Ortho-McNeil Janssen Scientific Affairs, Amorcyte, GE Healthcare, St. Jude Medical Inc., Medispec Limited, and Merck & Co.; and has equity interest in CV Therapeutics. Dr. Wong is a member of the Medical Advisory Board of Boston Scientific. Dr. Witzenbichler has received lecture fees from Boston Scientific and The Medicines Company. Dr. Guagliumi has received consulting fees from or has served on advisory boards for Abbott Vascular, Boston Scientific, Volcano, and Cordis; and receives grant support from Medtronic, Boston Scientific, Abbott, Lightlab, and Labcoat. Dr. Dudek reports receiving lecture fees from Nycomed; and research grants from or served as consultant/advisory board member for Abbott, Adamed, Biotronik, Balton, Bayer, BBRaun, BioMatrix, Boston Scientific, Boehringer Ingelheim, Bristol-Myers Squibb, Cordis, Cook, Eli Lilly, EuroCor, GlaxoSmithKline, Invatec, Medtronic, The Medicines Company, MSD, Nycomed, Orbus-Reich, Pfizer, Possis, Promed, Sanofi-Aventis, Siemens, Solvay, Terumo, and Tyco. Drs. Fahy and Lansky report being employed by the Cardiovascular Research Foundation. Dr. Stone reports receiving consulting fees from Medtronic, GlaxoSmithKline, Eli Lilly, and Bristol-Myers Squibb, and grant support from Boston Scientific, The Medicines Company, and Abbott Vascular. All other authors have reported that there are no relationships to disclose.
- Abbreviations and Acronyms
- acute myocardial infarction
- glycoprotein IIb/IIIa inhibitor
- left ventricular ejection fraction
- major adverse cardiovascular event(s)
- net adverse clinical event(s)
- percutaneous coronary intervention
- ST-segment elevation myocardial infarction
- Thrombolysis In Myocardial Infarction
- Received September 19, 2010.
- Revision received February 14, 2011.
- Accepted February 22, 2011.
- American College of Cardiology Foundation
- ↵
- ↵
- Kushner F.G.,
- Hand M.,
- Smith S.C. Jr..,
- et al.
- ↵
- Van de Werf F.,
- Bax J.,
- Betriu A.,
- et al.,
- ESC Committee for Practice Guidelines
- ↵
- ↵
- Cutlip D.E.,
- Windecker S.,
- Mehran R.,
- et al.
- ↵
- ↵
- ↵
- ↵
- ↵
- Sorajja P.,
- Gersh B.J.,
- Cox D.A.,
- et al.
- ↵
- Chan M.Y.,
- Andreotti F.,
- Becker R.C.
- Kereiakes D.J.,
- Gurbel P.A.
- ↵
- Hanratty C.G.,
- Koyama Y.,
- Rasmussen H.H.,
- Nelson G.I.C.,
- Hansen P.S.,
- Ward M.R.
- ↵
- ↵
- Ambrose J.A.
- ↵
- Politi L.,
- Sgura F.,
- Rossi R.,
- et al.
- ↵
- Toma M.,
- Buller C.E.,
- Westerhout C.M.,
- et al.,
- APEX-AMI Investigators
- ↵
- Dziewierz A.,
- Siudak Z.,
- Rakowski T.,
- Zasada W.,
- Dubiel J.S.,
- Dudek D.


text:
Click here to follow ▸@WebRTCSummit
Registration for the First International WebRTC Summit (@WebRTCSummit) is
now open. WebRTC Summit will take place Nov 6-7, 2013, at the Santa Clara
Convention Center, Santa Clara, CA.
WebRTC (Web Real-Time Communication) is an open source project supported by
Google, Mozilla and Opera that aims to enable browser-to-browser applications
for voice calling, video chat, and P2P file sharing without plugins. Its
mission is "To enable rich, high quality, RTC applications to be developed in
Register FREE for WebRTC Summit here ▸ http://bit.ly/1exOL9h
WebRTC Journal ▸Home
A survey by TokBox found that the WebRTC adoption rate among small
organizations is growing quickly where over 25% of developers say it is
important for their work.
WebRTC Summit will feature two full days of technical... (more)
How Containers Will Usher in a New Era of Cloud Computing
View Keynote ▸ Here
Download Slide Deck: ▸ Here
In his keynote at 19th Cloud Expo, Sheng Liang, co-founder and CEO of
Rancher Labs, discussed the technological advances and new business
opportunities created by the rapid adoption of containers. With the success
of Amazon Web Services (AWS) and various open source technologies used to
build private clouds, cloud computing has become an essential component of IT
View Keynote ▸ Here
Download Slide Deck: ▸ Here
However, users continue to face challenges in implementing clouds, as older
technologies evolve and newer ones like Docker containers gain prominence. He
explored these challenges and how to address them, while considering how
containers will influence the direction of cloud computing.
View Keynote ▸ Here
Download Slide Deck: ▸ Here
Speaker B... (more)
Given my (well-known and enduring) interest in all aspects of services, I
have followed Martin Fowler's writing on microservices. But I will admit I
always found the original paper more confusing than insightful. And in my
client work I have resisted the temptation to use a microservices pattern,
for precisely the reason that it would more than likely confuse. So I was
interested to see the book Building Microservices by Sam Newman published
last month, particularly as Newman is part of the Thoughtworks stable, which
presumably means it is authoritative.
Right off the bat, Newman advises that we should "think of microservices as a
specific approach for SOA in the same way that XP or Scrum are specific
approaches for Agile Software development". These analogies are very
interesting because my expectation was that microservices is a pattern. So I
might infer that micr... (more)
The World's Largest "Cloud Digital Transformation" Event
@CloudExpo / @ThingsExpo 2017 New York
(June 6-8, 2017, Javits Center, Manhattan)
@CloudExpo / @ThingsExpo 2017 Silicon Valley
(Oct. 31 - Nov. 2, 2017, Santa Clara Convention Center, CA)
Full Conference Registration Gold Pass and Exhibit Hall ▸ Here
Register For @CloudExpo ▸ Here via EventBrite
Register For @ThingsExpo ▸ Here via EventBrite
Register For @DevOpsSummit ▸ Here via EventBrite
Sponsorship Opportunities
Sponsors of Cloud Expo / @ThingsExpo will benefit from unmatched branding,
profile building and lead generation opportunities through:
Featured on-site presentation and ongoing on-demand webcast exposure to a
captive audience of industry decision-makers Showcase exhibition during our
new extended dedicated expo hours Breakout Session Priority scheduling for
Sponsors that have been guaranteed a 35 minut... (more)
The 20th International Cloud Expo has announced that its Call for Papers is
Cloud Expo, to be held June 6-8, 2017, at the Javits Center in New York City,
brings together Cloud Computing, Big Data, Internet of Things, DevOps,
Digital Transformation, Machine Learning and WebRTC to one location.
@CloudExpo / @ThingsExpo 2017 New York
(June 6-8, 2017, Javits Center, Manhattan)
@CloudExpo / @ThingsExpo 2017 Silicon Valley
(October 31 - November 2, 2017, Santa Clara Convention Center, CA)
Speaking Proposals ▸ Here
Topics will include:
APIs Architecture Artificial Intelligence Big Data & Analytics Business Apps
Cognitive Computing Containers Content Delivery Databases Deep Learning
Developer Community DevOps & Tools Digital Transformation Enterprise &
Migration Financial Technology Healthcare Machine Learning Microservices
Mobile Networking Security & Compliance Se... (more)
Financial Technology - or FinTech - Is Now Part of the @CloudExpo Program!
Accordingly, attendees at the upcoming 20th Cloud Expo at the Javits Center
in New York, June 6-8, 2017, will find fresh new content in a new track
called FinTech, which will incorporate machine learning, artificial
intelligence, deep learning, and blockchain into one track.
Financial enterprises in New York City, London, Singapore, and other world
financial capitals are embracing a new generation of smart, automated FinTech
that eliminates many cumbersome, slow, and expensive intermediate processes
from their businesses.
FinTech brings efficiency as well as the ability to deliver new services and
a much improved customer experience throughout the global financial services
industry. FinTech is a natural fit with cloud computing, as new services are
quickly developed, deployed, and scaled on p... (more)
At its core DevOps is all about collaboration. The lines of communication
must be opened and it takes some effort to ensure that they stay that way.
It's easy to pay lip service to trends and talk about implementing new
methodologies, but without action, real benefits cannot be realized. Success
requires planning, advocates empowered to effect change, and, of course, the
right tooling.
To bring about a cultural shift it's important to share challenges. In simple
terms, ensuring that everyone knows what everyone else is doing can create a
real team spirit and social cohesion that will drive DevOps forward. Here are
six tips that can be implemented to help you get there.
1. Stand-ups
A daily team meeting where people get an opportunity to review their progress
by addressing three simple questions:
What did I do yesterday? What will I do today? What might block me fro... (more)
@GonzalezCarmen has been ranked the Number One Influencer and @ThingsExpo has
been named the Number One Brand in the "M2M 2016: Top 100 Influencers and
Brands" by Onalytica.
Onalytica analyzed tweets over the last 6 months mentioning the keywords M2M
OR "Machine to Machine." They then identified the top 100 most influential
brands and individuals leading the discussion on Twitter.
Machine to Machine (M2M) refers to direct communication between devices using
any communications channel, including wired and wireless. The M2M market is
undergoing a fast transformation as enterprises are increasingly realizing
the value of connecting geographically dispersed people, devices, sensors and
machines to corporate networks. Today, industries such as healthcare,
automotive, oil and gas, precision agriculture, military, government, smart
cities/municipalities, manufacturing, a... (more)
"We formed Formation several years ago to really address the need for bring
complete modernization and software-defined storage to the more classic
private cloud marketplace," stated Mark Lewis, Chairman and CEO of Formation
Data Systems, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9,
2016, at the Javits Center in New York City, NY.
21st International Cloud Expo, taking place October 31 - November 2, 2017,
at the Santa Clara Convention Center in Santa Clara, CA, will feature
technical sessions from a rock star conference faculty and the leading
industry players in the world.
Download Show Prospectus ▸ Here
Cloud computing is now being embraced by a majority of enterprises of all
sizes. Yesterday's debate about public vs. private has transformed into the
reality of hybrid cloud: a recent survey shows that 74% of enterprises have a
hybrid cloud str... (more)
In today's enterprise, digital transformation represents organizational
change even more so than technology change, as customer preferences and
behavior drive end-to-end transformation across lines of business as well as
IT. To capitalize on the ubiquitous disruption driving this transformation,
companies must be able to innovate at an increasingly rapid pace.
Traditional approaches for driving innovation are now woefully inadequate for
keeping up with the breadth of disruption and change facing today's
increasingly digital enterprise. It's time to rethink how we innovate,
leveraging the very turbulence that drives the business to change.
In his Opening Keynote at 17th Cloud Expo, Jason Bloomberg, leading expert on
architecting agility for the enterprise and president of Intellyx, provided
a thought-provoking look at how modern digital practices, including
self-or... (more)
Download Slide Deck: ▸ Here
Download Slide Deck: ▸ Here
Fly Two Mistakes High - Keeping High Availability in the Cloud
When building large, cloud-based applications that operate at a high scale,
it's important to maintain a high availability and resilience to failures. In
order to do that, you must be tolerant of failures, even in light of failures
in other areas of your application.
Download Slide Deck: ▸ Here
"Fly two mistakes high" is an old adage in the radio control airplane hobby.
It means, fly high enough so that if you make a mistake, you can continue
flying with room to still make mistakes.
In his session at 18th Cloud Expo, Lee Atchison, Principal Cloud Architect
and Advocate at New Relic, discussed how this same philosophy can be applied
to highly scaled applications, and can dramatically increase your resilience
to failure.
Download Slide Deck: ▸ He... (more)
Terms of Use & Our Privacy Statement - About Newsfeeds / Videofeeds. Copyright ©1994-2018 DXWorldEXPO LLC. All Rights Reserved. All marks are trademarks of DXWorldEXPO LLC. Reproduction in whole or in part in any form or medium without express written permission of DXWorldEXPO LLC is prohibited.


text:
Discover how to ALWAYS pay 15% LESS on ALL Cheesecake Factory menu items even without Cheesecake Factory coupons, discounts, deals, or special savings! You can use these savings in addition to any Cheescake Factory coupons.Read More »
How to Get FREE Enfamil Baby Formula Samples (worth $600)
Discover Secret Hacks How to Get FREE Enfamil Baby Formula worth $600+! Get FREE Samples of Enfamil Formula in the Mail (no strings attached) EVERY month, as well as Free Baby Formula from other Top Brands. Plus HUGE baby food coupons and savings.Read More »